Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance

Thomas Kipps, MD, PhD, UC San Diego Moores Cancer Center, La Jolla, CA, discusses challenges associated with the use of BTK inhibitors (BTKis) for the treatment of chronic lymphocytic leukemia (CLL). Prof. Kipps expresses optimism about the development of BTK degraders, which may provide a solution to these issues. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.